Literature DB >> 25218650

Mechanisms of glucocorticoid action and insensitivity in airways disease.

C Boardman1, L Chachi2, A Gavrila2, C R Keenan3, M M Perry1, Y C Xia3, H Meurs4, P Sharma5.   

Abstract

Glucocorticoids are the mainstay for the treatment of chronic inflammatory diseases including asthma and chronic obstructive pulmonary disease (COPD). However, it has been recognized that glucocorticoids do not work well in certain patient populations suggesting reduced sensitivity. The ultimate biologic responses to glucocorticoids are determined by not only the concentration of glucocorticoids but also the differences between individuals in glucocorticoid sensitivity, which is influenced by multiple factors. Studies are emerging to understand these mechanisms in detail, which would help in increasing glucocorticoid sensitivity in patients with chronic airways disease. This review aims to highlight both classical and emerging concepts of the anti-inflammatory mechanisms of glucocorticoids and also review some novel strategies to overcome steroid insensitivity in airways disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Asthma; Chronic airway diseases; Combination therapy; Glucocorticoid; Inflammation; Steroid resistance

Mesh:

Substances:

Year:  2014        PMID: 25218650     DOI: 10.1016/j.pupt.2014.08.008

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  21 in total

1.  Can GPCRs Be Targeted to Control Inflammation in Asthma?

Authors:  Pawan Sharma; Raymond B Penn
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two "real-life" studies.

Authors:  Wenjing Ye; Xuejun Guo; Tianyun Yang; Fengfeng Han
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 3.  Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

Authors:  Tonio Pera; Raymond B Penn
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310

Review 4.  Glucocorticoid-independent modulation of GR activity: Implications for immunotherapy.

Authors:  Janet P Hapgood; Chanel Avenant; Johnson M Moliki
Journal:  Pharmacol Ther       Date:  2016-06-08       Impact factor: 12.310

5.  Glucocorticoid and TNF signaling converge at A20 (TNFAIP3) to repress airway smooth muscle cytokine expression.

Authors:  Sarah K Sasse; Mohammed O Altonsy; Vineela Kadiyala; Gaoyuan Cao; Reynold A Panettieri; Anthony N Gerber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-07-01       Impact factor: 5.464

6.  BET bromodomains regulate transforming growth factor-β-induced proliferation and cytokine release in asthmatic airway smooth muscle.

Authors:  Mark M Perry; Andrew L Durham; Philip J Austin; Ian M Adcock; Kian Fan Chung
Journal:  J Biol Chem       Date:  2015-02-19       Impact factor: 5.157

7.  Impaired anti-inflammatory action of glucocorticoid in neutrophil from patients with steroid-resistant asthma.

Authors:  Meijia Wang; Pengfei Gao; Xiaojie Wu; Yuetao Chen; Yikuan Feng; Qun Yang; Yongjian Xu; Jianping Zhao; Jungang Xie
Journal:  Respir Res       Date:  2016-11-16

Review 8.  Emerging pharmaceutical therapies for COPD.

Authors:  Sowmya P Lakshmi; Aravind T Reddy; Raju C Reddy
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-07-21

9.  Indirubin, a bisindole alkaloid from Isatis indigotica, reduces H1N1 susceptibility in stressed mice by regulating MAVS signaling.

Authors:  Chong Jie; Zhuo Luo; Huan Chen; Min Wang; Chang Yan; Zhong-Fu Mao; Gao-Keng Xiao; Hiroshi Kurihara; Yi-Fang Li; Rong-Rong He
Journal:  Oncotarget       Date:  2017-11-09

10.  Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.

Authors:  Donald H Arnold; Sara L Van Driest; Theodore F Reiss; Jennifer C King; Wendell S Akers
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.